Audrey Sigmund
@ASigmundMD
Followers
349
Following
478
Media
19
Statuses
474
Assistant Professor in Lymphoma @OSUHematology. @NUFeinbergMed alum. Interested in #lymsm #MedEd #WomenInMedicine #HemeSurvivorship. Views are my own.
Columbus, OH
Joined September 2014
Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it. Read the review “Strategies to Reinvigorate the Bedside
10
150
422
Learn more about clinical outcomes with a treatment option for 3L+ DLBCL adult patients. Click here https://t.co/RYRWtNdb6r to discover clinical trial efficacy, safety data, dosing, monitoring & management considerations for select adverse reactions, and more.
0
1
5
Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics | Blood Advances | American Society of Hematology
ashpublications.org
Key PointsctDNA levels correlated with PET-CT–based TMTV and may enable earlier relapse detection than imaging alone.A rapid ∼100-fold median reduction in
0
6
21
Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma
aacrjournals.org
Abstract. Purpose: Polatuzumab vedotin (polatuzumab) was approved for upfront treatment of diffuse large B-cell lymphoma (DLBCL) in combination with chemoimmunotherapy (Pola-R-CHP) based on the...
0
15
50
Optimising treatment strategies in older patients with mantle cell lymphoma - The Lancet
0
11
39
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? https://t.co/rFW0XwVqPT Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer
ashpublications.org
Although there have been many therapeutic advances in follicular lymphoma (FL) in recent years, important questions remain about how best to integrate emer
0
14
54
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology
ashpublications.org
Key Points. Population-wide introduction of DA-EPOCH-R is associated with improved outcomes in HGBCL-DH-BCL2 with DLBCL morphology.The most notable improve
0
16
62
#Hematology Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell #Lymphoma #DLBCL | Journal of Clinical Oncology @JCO_ASCO #lymsm
ascopubs.org
In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free...
0
7
14
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study
ashpublications.org
Key Points. Pirtobrutinib demonstrates efficacy in relapsed/refractory follicular lymphoma with an ORR of 52.1% and median DOR of 10.2 monthsPirtobrutinib
0
6
35
This study followed 873 patients with mantle cell lymphoma (MCL) for a median of 7 years. The 5-year incidence of MCL in CNS was only 2.8%, but 9.9% for those with blastoid/pleomorphic subtype. https://t.co/rxcJ3jmVE5
0
11
38
🚨 AI won’t replace doctors… but it can prevent them from learning how to think. A critical article in @NEJM shows that if introduced too early in medical training, it weakens clinical reasoning. ✅ A good doctor will always need critical thinking. N Engl J Med 2025;393:786
28
430
1K
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. @JCO_ASCO
ascopubs.org
We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large...
0
7
36
Survival after incidental vs symptomatic FL: - 908 pts, 29% incidental - incidental: more early stage & normal LDH - no diff in EFS, lymphoma-specific survival, or OS between groups We can answer the "what if this was picked up earlier" question! #lymsm
https://t.co/dzcNNM0V2Z
0
18
57
Want to pursue a clinical career in malignant #hematology but not sure where to start? The ASH Malignant Hematology Mentorship Program matches you with an experienced mentor who’s walked the path you're on. Apply now: https://t.co/iQfsDd6Vjg
0
5
12
#Hematology Outcomes of bispecific antibody therapy after #CARTcell failure in relapsed/refractory large B-cell #lymphoma #DLBCL | Blood Advances | American Society of Hematology #lymsm
ashpublications.org
Key PointsEarly relapse after CAR-T (≤3 months) is associated with poor outcome of subsequent BsAb therapy.Lactate dehydrogenase, higher International Prog
0
9
35
Networking for a successful career in clinical hematology: a strategic approach | Published in Clinical Hematology International, the official peer-reviewed academic open access journal of @TheIACH @RahulBanerjeeMD @EHA_Hematology
chi.scholasticahq.com
By Mohamad Mohty, Rahul Banerjee. Networking is fundamental to career development in clinical hematology, providing avenues for knowledge exchange, collaborations, and professional growth.
1
15
33
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology
annalsofoncology.org
The treatment landscape for many lymphoma entities continues to evolve rapidly, with multiple recent approvals of novel non-chemotherapy (ChT)-based approaches. The following Clinical Practice...
4
44
119
Rigorous,goal-concordant career development is a mandate for modern training and sustenance of our work force to meet patients’ and society’s needs. Check out our latest work on training for community-based careers: https://t.co/kGr8UeDegD
#HemOncMedEd @ASCO @rushadpatell
ascopubs.org
PURPOSEHematology/oncology (HO) care in the United States is predominantly delivered in community-based (CB) settings. We aimed to explore attitudes of HO fellowship program leaders (PLs) surrounding...
2
7
27
Teaching Communication Skills and Developing Comfort With Difficult Conversations: A Combined Palliative Care-Oncology Simulation Session for Hematology/ Oncology Fellows. Read the full article.
ascopubs.org
PURPOSEASCO strongly endorses the integration of palliative care (PC) to improve outcomes and support patients in their cancer trajectories. Developing core PC skills for trainees is essential, with...
0
2
11
Interested in a mentor to guide your career in malignant #hematology? Apply for ASH’s new Mentorship Program, and grow your network! Deadline: Sept 26. Apply today! 🔗 https://t.co/QgTdWwsDWD Interested in becoming a mentor? Sign up today: https://t.co/fZ2Q7rbLLz
1
9
18